Immunogenicity analysis of decellularized cardiac scaffolds after transplantation into rats

References

• 1 Alghazali KM, Nima ZA, Hamzah RN et al. Bone-tissue engineering: complex tunable structural and biological responses to injury, drug delivery, and cell-based therapies. Drug Metab. Rev. 47(4), 1–24 (2015).
  Google Scholar
• 2 Karunaratne A, Xi L, Bentley L et al. Multiscale alterations in bone matrix quality increased fragility in steroid induced osteoporosis. Bone 84, 15–24 (2016).
  Medline CASGoogle Scholar
• 3 Santiago-Medina P, Sundaram PA, Diffoot-Carlo N. Titanium oxide: a bioactive factor in osteoblast differentiation. Int. J. Dent. 2015, 357653 (2015).
  Medline CASGoogle Scholar
• 4 Chapple CR, Osman NI, Mangera A et al. Application of tissue engineering to pelvic organ prolapse and stress urinary incontinence. Low. Urin. Tract Symptoms 7(2), 63–70 (2015).
  Medline CASGoogle Scholar
• 5 Li Z, Zhang M. Chitosan-alginate as scaffolding material for cartilage tissue engineering. J. Biomed. Mater. Res. Part A 75(2), 485–493 (2005).
  MedlineGoogle Scholar
• 6 Glowacki J, Mizuno S. Collagen scaffolds for tissue engineering. Biopolymers 89(5), 338–344 (2008).
  Medline CASGoogle Scholar
• 7 Hoque ME, Nuge T, Yeow TK, Nordin N, Prasad RGSV. Gelatin based scaffolds for tissue engineering – a review. Polym. Res. J. 9(1), 15–32 (2014).
  Google Scholar
• 8 Zhu J, Marchant RE. Design properties of hydrogel tissue-engineering scaffolds. Expert Rev. Med. Devices 8(5), 607–626 (2011).
  MedlineGoogle Scholar
• 9 Nayak KK, Gupta P. In vitro biocompatibility study of keratin/agar scaffold for tissue engineering. Int. J. Biol. Macromol. 81, 1–10 (2015).
  Medline CASGoogle Scholar
• 10 Stupp SI, Ciegler GW. Organoapatites: materials for artificial bone. I. Synthesis and microstructure. J. Biomed. Mater. Res. 26(2), 169–183 (1992).
  Medline CASGoogle Scholar
• 11 Cahn F KT. Generation of an artificialskin construct containing a non-degradable fiber mesh: a potential transcutaneous interface. Biomed Mater. 3(3), 1–17 (2008).
  Google Scholar
• 12 Quint C, Kondo Y, Manson RJ et al. Decellularized tissue-engineered blood vessel as an arterial conduit. Proc. Natl Acad. Sci. USA 108(22), 9214–9219 (2011).
  Medline CASGoogle Scholar
• 13 Schaner PJ, Martin ND, Tulenko TN et al. Decellularized vein as a potential scaffold for vascular tissue engineering. J. Vasc. Surg. 40(1), 146–153 (2004).
  MedlineGoogle Scholar
• 14 Ling C, Li Q, Brown ME et al. Bioengineered vocal fold mucosa for voice restoration. Sci. Transl. Med. 7(314), 314ra187–314ra187 (2015).
  MedlineGoogle Scholar
• 15 Ott HC, Matthiesen TS, Goh S-K et al. Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart. Nat. Med. 14(2), 213–221 (2008).
  Medline CASGoogle Scholar
• 16 Uzarski JS, Xia Y, Belmonte JCI, Wertheim JA. New strategies in kidney regeneration and tissue engineering. Curr. Opin. Nephrol. Hypertens. 23(4), 399–405 (2014).
  Medline CASGoogle Scholar
• 17 Palakkan AA, Hay DC, Anil Kumar PR, Kumary TV, Ross JA. Liver tissue engineering and cell sources: issues and challenges. Liver Int. 33(5), 666–676 (2013).
  Medline CASGoogle Scholar
• 18 Faulk DM, Wildemann JD, Badylak SF. Decellularization and cell seeding of whole liver biologic scaffolds composed of extracellular matrix. J. Clin. Exp. Hepatol. 5(1), 69–80 (2015).
  MedlineGoogle Scholar
• 19 Atala A. Tissue engineering of human bladder. Br. Med. Bull. 97, 81–104 (2011).
  MedlineGoogle Scholar
• 20 Kador KE, Montero RB, Venugopalan P et al. Tissue engineering the retinal ganglion cell nerve fiber layer. Biomaterials 34(17), 4242–4250 (2013).
  Medline CASGoogle Scholar
• 21 Yu Y, Alkhawaji A, Ding Y, Mei J. Decellularized scaffolds in regenerative medicine. Oncotarget 7(36), 58671–58683 (2016).
  MedlineGoogle Scholar
• 22 Rana D, Zreiqat H, Benkirane-Jessel N, Ramakrishna S, Ramalingam M. Development of decellularized scaffolds for stem cell-driven tissue engineering. J. Tissue Eng. Regen. Med. 11(4), 942–965 (2017).
  Medline CASGoogle Scholar
• 23 Tapias LF, Ott HC. Decellularized scaffolds as a platform for bioengineered organs. Curr. Opin. Organ Transplant. 19(2), 145–152 (2014).
  Medline CASGoogle Scholar
• 24 Hussein KH, Park K-M, Kang K-S, Woo H-M. Biocompatibility evaluation of tissue-engineered decellularized scaffolds for biomedical application. Mater. Sci. Eng. C 67, 766–778 (2016).
  Medline CASGoogle Scholar
• 25 Crapo PM, Medberry CJ, Reing JE et al. Biologic scaffolds composed of central nervous system extracellular matrix. Biomaterials 33(13), 3539–3547 (2012).
  Medline CASGoogle Scholar
• 26 Billingham ME, Cary NR, Hammond ME et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J. Heart Transplant. 9(6), 587–593 (2017).
  Google Scholar
• 27 Go AS, Mozaffarian D, Roger VL et al. Heart disease and stroke statistics – 2014 update: a report from the American Heart Association. Circulation 129(3), e28 (2014).
  MedlineGoogle Scholar
• 28 Moroni F, Mirabella T. Decellularized matrices for cardiovascular tissue engineering. Am. J. Stem Cells 3(1), 1–20 (2014).
  Medline CASGoogle Scholar
• 29 Weymann A, Patil NP, Sabashnikov A et al. Bioartificial heart: a human-sized porcine model – the way ahead. PLoS ONE 9(11), e111591 (2014).
  MedlineGoogle Scholar
• 30 Boeer U, Buettner FFR, Klingenberg M et al. Immunogenicity of intensively decellularized equine carotid arteries is conferred by the extracellular matrix protein collagen type VI. PLoS ONE 9(8), e105964 (2014).
  MedlineGoogle Scholar
• 31 Ayala García MA, González Yebra B, López Flores AL, Guaní Guerra E. The major histocompatibility complex in transplantation. J. Transplant. 2012, 1–7 (2012).
  Google Scholar
• 32 Hricik DE. Transplant immunology and immunosuppression: core curriculum 2015. Core Curric. Nephrol. 65(6), 956–966 (2015).
  Google Scholar
• 33 Moreau A, Varey E, Anegon I, Cuturi M-C. Effector mechanisms of rejection. Cold Spring Harb. Perspect. Med. 3(11), 1–33 (2013).
  Google Scholar
• 34 Hancock WW, Gao W, Shemmeri N et al. Immunopathogenesis of accelerated allograft rejection in sensitized recipients: humoral and nonhumoral mechanisms. Transplantation 73(9), 1392–1397 (2002).
  MedlineGoogle Scholar
• 35 Sánchez-Fueyo A, Strom TB. Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs. Gastroenterology 140(1), 51–64 (2011).
  MedlineGoogle Scholar
• 36 Michaels PJ, Fishbein MC, Colvin RB. Humoral rejection of human organ transplants. Springer Semin. Immunopathol. 25(2), 119–140 (2003).
  MedlineGoogle Scholar
• 37 Ingulli E. Mechanism of cellular rejection in transplantation. Pediatr. Nephrol. 25(1), 61–74 (2010).
  MedlineGoogle Scholar
• 38 Zhao Y, Zhang S, Zhou J et al. Biomaterials The development of a tissue-engineered artery using decellularized scaffold and autologous ovine mesenchymal stem cells. Biomaterials 31(2), 296–307 (2010).
  MedlineGoogle Scholar
• 39 Jiao Z-X, Leng Y, Xia J-J et al. As₂ O₃ combined with leflunomide prolongs heart xenograft survival via suppressing the response of Th1, Th2, and B cells in a rat model. Xenotransplantation 23(3), 237–248 (2016).
  MedlineGoogle Scholar
• 40 Oberhuber R, Cardini B, Kofler M et al. Murine cervical heart transplantation model using a modified cuff technique. J. Vis. Exp. (92), e50753 (2014).
  MedlineGoogle Scholar
• 41 Xiao F, Chong AS, Foster P et al. Leflunomide controls rejection in hamster to rat cardiac xenografts. Transplantation 58(7), 828–834 (1994).
  Medline CASGoogle Scholar
• 42 Billingham ME, Cary NR, Hammond ME et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J. Heart Transplant. 9(6), 587–593 (1990).
  Medline CASGoogle Scholar
• 43 Platt JL. Antibodies in transplantation. Discov. Med. 10(51), 125–133 (2010).
  MedlineGoogle Scholar
• 44 Lynch RJ, Platt JL. Accommodation in organ transplantation. Curr. Opin. Organ Transplant. 13(2), 165–170 (2008).
  MedlineGoogle Scholar
• 45 Chang AT, Platt JL. The role of antibodies in transplantation. Transplant. Rev. (Orlando). 23(4), 191–198 (2009).
  MedlineGoogle Scholar
• 46 LaRosa DF, Rahman AH, Turka LA. The innate immune system in allograft rejection and tolerance. J. Immunol. 178(12), 7503–7509 (2007).
  Medline CASGoogle Scholar
• 47 Lakkis FG, Lechler RI. Origin and biology of the allogeneic response. Cold Spring Harb. Perspect. Med. 3(8), a014993 (2013).
  MedlineGoogle Scholar
• 48 Dijke EI, Platt JL, Blair P et al. B cells in transplantation. J. Heart Lung Transplant. 35(6), 704–710 (2016).
  MedlineGoogle Scholar
• 49 Kloc M, Ghobrial RM. Chronic allograft rejection: a significant hurdle to transplant success. Burn. Trauma. 2(1), 3–10 (2014).
  MedlineGoogle Scholar
• 50 Badylak SF, Gilbert TW. Immune response to biologic scaffold materials. Semin. Immunol. 20(2), 109–116 (2008).
  Medline CASGoogle Scholar
• 51 McKeown DW, Bonser RS, Kellum JA. Management of the heartbeating brain-dead organ donor. Br. J. Anaesth. 108, i96–i107 (2012).
  MedlineGoogle Scholar
• 52 Linden PK. History of solid organ transplantation and organ donation. Crit. Care Clin. 25(1), 165–184 (2009).
  MedlineGoogle Scholar
• 53 Saidi RF, Hejazii Kenari SK. Challenges of organ shortage for transplantation: solutions and opportunities. Int. J. Organ Transplant. Med. 5(3), 87–96 (2014).
  Medline CASGoogle Scholar
• 54 Beyar R. Challenges in organ transplantation. Rambam Maimonides Med. J. 2(2), e0049 (2011).
  MedlineGoogle Scholar
• 55 Calne R. Clinical transplantation: current problems, possible solutions. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 360(1461), 1797–1801 (2005).
  MedlineGoogle Scholar
• 56 Murphy PG, Smith M. Towards a framework for organ donation in the UK. Br. J. Anaesth. 108(Suppl. 1), i56–i67 (2012).
  MedlineGoogle Scholar
• 57 Rudge C, Matesanz R, Delmonico FL, Chapman J. International practices of organ donation. Br. J. Anaesth. 108, i48–i55 (2012).
  MedlineGoogle Scholar
• 58 Tam PPL, Rossant J, Skarnes WC, Beddington RS. Mouse embryonic chimeras: tools for studying mammalian development. Development 130(25), 6155–6163 (2003).
  Medline CASGoogle Scholar
• 59 Isotani A, Hatayama H, Kaseda K, Ikawa M, Okabe M. Formation of a thymus from rat ES cells in xenogeneic nude mouse – rat ES chimeras. Genes Cells 16(4), 397–405 (2011).
  Medline CASGoogle Scholar
• 60 Eckardt S, McLaughlin KJ, Willenbring H. Mouse chimeras as a system to investigate development, cell and tissue function, disease mechanisms and organ regeneration. Cell Cycle 10(13), 2091–2099 (2011).
  Medline CASGoogle Scholar
• 61 Conner DA. Chimeric mouse production by microinjection. In: Current Protocols in Molecular Biology. John Wiley & Sons, Inc., NJ, USA, 23.7.1–23.7.20 (2001).
  Google Scholar
• 62 Gardner RL, Johnson MH. Investigation of early mammalian development using interspecific chimaeras between rat and mouse. Nat. New Biol. 246(151), 86–89 (1973).
  Medline CASGoogle Scholar
• 63 Wu J, Platero-Luengo A, Sakurai M et al. Interspecies chimerism with mammalian pluripotent stem cells. Cell 168(3), 473–486.e15 (2017).
  Medline CASGoogle Scholar
• 64 Mueller S, Prelle K, Rieger N et al. Chimeric pigs following blastocyst injection of transgenic porcine primordial germ cells. Mol. Reprod. Dev. 54(3), 244–254 (1999).
  Medline CASGoogle Scholar
• 65 Akimkin V, Beer M, Blome S et al. New chimeric porcine coronavirus in swine feces, Germany, 2012. Emerg. Infect. Dis. 22(7), 1314–1315 (2016).
  Medline CASGoogle Scholar
• 66 Behringer RR. Human-animal chimeras in biomedical research. Cell Stem Cell. 1(3), 259–262 (2007).
  Medline CASGoogle Scholar
• 67 Aasen T, Raya A, Barrero MJ et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat. Biotechnol. 26(11), 1276–1284 (2008).
  Medline CASGoogle Scholar
• 68 Cong L, Ran FA, Cox D et al. Multiplex genome engineering using CRISPR/Cas systems. Science (80-.). 339(6121), 819–823 (2013).
  Medline CASGoogle Scholar
• 69 Cyranoski D, Ledford H. International outcry over genome-edited baby claim. Nature 563, 607–608 (2018).
  Medline CASGoogle Scholar
• 70 Hyun I, Taylor P, Testa G et al. Ethical standards for human-to-animal chimera experiments in stem cell research. Cell Stem Cell. 1(2), 159–163 (2007).
  MedlineGoogle Scholar
• 71 van Sandwijk MS, Bemelman FJ, Ten Berge IJM. Immunosuppressive drugs after solid organ transplantation. Neth. J. Med. 71(6), 281–289 (2013).
  Medline CASGoogle Scholar
• 72 van Gelder T, van Schaik RH, Hesselink DA. Pharmacogenetics and immunosuppressive drugs in solid organ transplantation. Nat. Rev. Nephrol. 10(12), 725–731 (2014).
  Medline CASGoogle Scholar
• 73 Starzl TE, Makowka L. Organ transplantation – then and now. Hosp. Physician 23(8), 28–33, 36 (1987).
  Medline CASGoogle Scholar
• 74 Griesemer A, Yamada K, Sykes M. Xenotransplantation: immunological hurdles and progress toward tolerance. Immunol. Rev. 258(1), 241–258 (2014).
  Medline CASGoogle Scholar
• 75 Nie X, Wang D-A. Decellularized orthopaedic tissue-engineered grafts: biomaterial scaffolds synthesised by therapeutic cells. Biomater. Sci. 6(11), 2798–2811 (2018).
  Medline CASGoogle Scholar
• 76 Stoppel WL, Hu D, Domian IJ, Kaplan DL, Black LD. Anisotropic silk biomaterials containing cardiac extracellular matrix for cardiac tissue engineering. Biomed. Mater. 10(3), 034105 (2015).
  MedlineGoogle Scholar
• 77 Chen W, Konkel JE. TGF-beta and ‘adaptive’ Foxp3(+) regulatory T cells. J. Mol. Cell Biol. 2(1), 30–36 (2010).
  Medline CASGoogle Scholar